In addition, anti-PD-1/PD-L1 immunotherapy represents a major breakthrough in the treatment of NSCLC, as the analysis of PD-L1 expression has enabled the identification of patients with an increased likelihood of response to immunotherapy [154]. Here, PDCD1 is linked to non-small cell lung carcinoma.